Guangdong Zhongsheng Pharmaceutical (SHE:002317) received clinical trial approval from China's National Medical Products Administration for its onradivir tablets, according to a Thursday filing with the Shenzhen bourse.
The application is for the indication of influenza A with high complication risk, the filing said.
Shares in the drug maker rose 1% during the afternoon session on Thursday.